Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?

J Acquir Immune Defic Syndr. 2021 Mar 1;86(3):e80-e82. doi: 10.1097/QAI.0000000000002557.

Authors

Matthew E Levy^{1

2}, Anya Agopian¹, Manya Magnus¹, Anthony Rawls¹, Jenevieve Opoku³, Michael Kharfen³, Alan E Greenberg¹, Irene Kuo¹

Affiliations

¹ Department of Epidemiology,Milken Institute School of Public Health at the George Washington University,Washington, DC.
² Westat, Rockville, MD.
³ District of Columbia Department of Health, HIV/AIDS, Hepatitis,STD, and TB Administration,Washington, DC.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Adult
Anti-HIV Agents / administration & dosage
Anti-HIV Agents / therapeutic use*
Delayed-Action Preparations
District of Columbia / epidemiology
HIV Infections / prevention & control*
Homosexuality, Male*
Humans
Male
Pre-Exposure Prophylaxis / methods*
Pyridones / administration & dosage
Pyridones / therapeutic use*

Substances

Anti-HIV Agents
Delayed-Action Preparations
Pyridones
cabotegravir

Grants and funding